Erythema multiforme major associated with molnupiravir treatment for SARS-CoV-2 infection: First report
- PMID: 37016985
- DOI: 10.1111/jdv.19099
Erythema multiforme major associated with molnupiravir treatment for SARS-CoV-2 infection: First report
References
REFERENCES
-
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.
-
- Dastoli S, Bennardo L, Patruno C, Nisticò SP. Are erythema multiforme and urticaria related to a better outcome of COVID-19? Dermatol Ther. 2020;33(4):e13681.
-
- Bennardo L, Nisticò SP, Dastoli S, Provenzano E, Napolitano M, Silvestri M, et al. Erythema Multiforme and COVID-19: what do we know? Medicina (Kaunas). 2021;57(8):828.
-
- García-Gil MF, García García M, Monte Serrano J, Prieto-Torres L, Ara-Martín M. Acral purpuric lesions (erythema multiforme type) associated with thrombotic vasculopathy in a child during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2020;34(9):e443-5.
-
- Manji KP, Mwaniki G, Simba AA, Makani J. Erythema multiforme in a young adult following COVID-19 infection and vaccination in Tanzania. BMJ Case Rep. 2022;15(5):e247168.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous